Palm DesertPalm DesertInvestor Relations Mon - Fri - 7:00 - 5:00 1-510-330-1888 Mon - Fri - 6:30 - 1:00 1-510-330-1888 ext-1

Segment Wealth Management Has Cut Merck & Co (MRK) Stake; Methode Electronics (MEI) SI Increased By 2.7%

Full Alliance Group, Inc. | The Cutting Edge of Health | > Blog > Segment Wealth Management Has Cut Merck & Co (MRK) Stake; Methode Electronics (MEI) SI Increased By 2.7%


Methode Electronics, Inc. (NYSE:MEI) Logo

Methode Electronics Inc (NYSE:MEI) had an increase of 2.7% in short interest. MEI’s SI was 1.22 million shares in March as released by FINRA. Its up 2.7% from 1.19M shares previously. With 190,000 avg volume, 6 days are for Methode Electronics Inc (NYSE:MEI)’s short sellers to cover MEI’s short positions. The SI to Methode Electronics Inc’s float is 3.48%. The stock increased 2.25% or $0.66 during the last trading session, reaching $30.02. About 261,735 shares traded. Methode Electronics, Inc. (NYSE:MEI) has declined 23.63% since March 22, 2018 and is downtrending. It has underperformed by 28.00% the S&P500. Some Historical MEI News: 24/05/2018 – Methode Electronics Closes Below 200-Day Average: Technicals; 12/03/2018 – METHODE ELECTRONICS INC MEI.N – RONALD TSOUMAS, CURRENTLY METHODE’S CONTROLLER AND TREASURER, HAS BEEN PROMOTED TO SUCCEED HRUDICKA; 12/03/2018 – METHODE ELECTRONICS INC MEI.N – CHIEF FINANCIAL OFFICER JOHN HRUDICKA HAS LEFT COMPANY EFFECTIVE TODAY TO PURSUE OTHER OPPORTUNITIES; 12/03/2018 – METHODE ELECTRONICS, REPORTS CFO CHANGE; 12/03/2018 Methode Electronics, Inc. Announces CFO Change; 24/05/2018 – JSE: MEI – CHIEF EXECUTIVE OFFICER TO CONTINUE AS A NON-EXECUTIVE DIRECTOR; 29/05/2018 – Trivedi Global, Inc. and Su-Mei Liu Announce Research Results on the Impact of a Biofield Energy Treated Nutraceutical for Decr; 12/03/2018 – Methode Electronics Names Ronald Tsoumas CFO; 22/03/2018 – SHOUGANG CONCORD GRAND NAMES CHAN SO MEI AS COMPANY SECRETARY; 29/05/2018 – Trivedi Global, Inc. and Su-Mei Liu Announce the Research Results on the Impact of a Biofield Energy Treated Nutraceutical for Decreasing Autoimmune and lnflammatory Disorders

Segment Wealth Management Llc decreased Merck & Co Inc (MRK) stake by 32.45% reported in 2018Q4 SEC filing. Segment Wealth Management Llc sold 7,971 shares as Merck & Co Inc (MRK)’s stock rose 5.36%. The Segment Wealth Management Llc holds 16,593 shares with $1.27M value, down from 24,564 last quarter. Merck & Co Inc now has $214.11B valuation. The stock increased 1.06% or $0.87 during the last trading session, reaching $82.95. About 9.04 million shares traded. Merck & Co., Inc. (NYSE:MRK) has risen 51.53% since March 22, 2018 and is uptrending. It has outperformed by 47.16% the S&P500. Some Historical MRK News: 23/05/2018 – STRATA ONCOLOGY FUNDING ROUND LED PFIZER, MERCK & CO; 23/05/2018 – Merck: Keytruda Has Shown Improved Survival Benefit in Advanced NSCLC in Five Phase 3 Trials; 16/04/2018 – BRISTOL-MYERS SQUIBB – IN PHASE 3 CHECKMATE -214 CLINICAL TRIAL, OPDIVO + YERVOY COMBINATION DEMONSTRATED A SIGNIFICANT INCREASE IN OVERALL SURVIVAL; 24/04/2018 – ELI LILLY – 2018 REV GROWTH ALSO EXPECTED TO BE DRIVEN BY NEW PRODUCTS INCLUDING VERZENIO, CYRAMZA, OLUMIANT, LARTRUVO; 02/05/2018 – MERCK KGAA TO DEVELOP ABITUZUMAB WITH SFJ PHARMACEUTICALS GROUP; 03/05/2018 – Moderna Therapeutics received an additional $125 million in funding through an expanded partnership with Merck around a personalized cancer vaccine; 23/03/2018 – ANTICANCER AGENT LENVIMA® (LENVATINIB MESYLATE) APPROVED FOR ADDITIONAL INDICATION OF UNRESECTABLE HEPATOCELLULAR CARCINOMA (HCC) IN JAPAN, FIRST APPROVAL WORLDWIDE FOR LENVIMA FOR HCC; 06/04/2018 – Incyte’s new immunotherapy drug epacadostat failed to work in conjunction with Merck’s blockbuster melanoma drug Keytruda; 06/04/2018 – NewLink Will Review Clinical Programs After Merck, Incyte Trial Failure — MarketWatch; 07/03/2018 – MERCK & CO. WILL PAY EISAI AN UPFRONT PAYMENT OF $300M

Methode Electronics, Inc. designs, manufactures, and markets component and subsystem devices worldwide. The company has market cap of $1.11 billion. The firm operates through four divisions: Automotive, Interface, Power Products, and Other. It has a 10.67 P/E ratio. The Automotive segment offers electronic and electro-mechanical devices, and related products to automobile original equipment manufacturers directly or through their tiered suppliers.

More notable recent Methode Electronics, Inc. (NYSE:MEI) news were published by: Globenewswire.com which released: “Methode Electronics’ Board Approves Dividend NYSE:MEI – GlobeNewswire” on March 15, 2019, also Globenewswire.com with their article: “Methode Electronics to Announce Third-Quarter Fiscal 2019 Results on Thursday, March 7, 2019 – GlobeNewswire” published on February 21, 2019, Seekingalpha.com published: “Methode Electronics, Inc. (MEI) CEO Donald Duda on Q3 2019 Results – Earnings Call Transcript – Seeking Alpha” on March 07, 2019. More interesting news about Methode Electronics, Inc. (NYSE:MEI) were released by: Benzinga.com and their article: “Benzinga’s Top Upgrades, Downgrades For March 8, 2019 – Benzinga” published on March 08, 2019 as well as Benzinga.com‘s news article titled: “Earnings Scheduled For March 7, 2019 – Benzinga” with publication date: March 07, 2019.

Among 2 analysts covering Methode Electronics (NYSE:MEI), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Methode Electronics had 6 analyst reports since October 1, 2018 according to SRatingsIntel. The company was maintained on Friday, March 8 by FBR Capital. The firm earned “Outperform” rating on Tuesday, December 4 by Robert W. Baird. The firm has “Neutral” rating by Robert W. Baird given on Monday, October 1.

Among 8 analysts covering Merck u0026 Co (NYSE:MRK), 7 have Buy rating, 0 Sell and 1 Hold. Therefore 88% are positive. Merck u0026 Co had 13 analyst reports since October 11, 2018 according to SRatingsIntel. The company was initiated on Monday, February 25 by UBS. The stock has “Buy” rating by Citigroup on Wednesday, October 31. The firm earned “Outperform” rating on Monday, October 22 by BMO Capital Markets. The company was maintained on Tuesday, October 16 by Citigroup. The firm has “Hold” rating by BMO Capital Markets given on Friday, March 1. The stock has “Buy” rating by Cantor Fitzgerald on Thursday, February 21. On Monday, March 4 the stock rating was maintained by Cantor Fitzgerald with “Buy”. Argus Research maintained it with “Buy” rating and $95 target in Wednesday, February 20 report. The firm has “Buy” rating by SunTrust given on Monday, October 29. The firm has “Buy” rating given on Tuesday, March 12 by Cantor Fitzgerald.

Investors sentiment decreased to 0.92 in Q4 2018. Its down 0.01, from 0.93 in 2018Q3. It dropped, as 37 investors sold MRK shares while 660 reduced holdings. 157 funds opened positions while 485 raised stakes. 1.94 billion shares or 3.54% more from 1.87 billion shares in 2018Q3 were reported. Banque Pictet & Cie holds 169,643 shares or 0.26% of its portfolio. Parkside Commercial Bank And Tru reported 15,982 shares. Auxier Asset Mgmt owns 132,056 shares. Eqis Capital Mgmt has 0.13% invested in Merck & Co., Inc. (NYSE:MRK). Macnealy Hoover Inv Mgmt accumulated 17,983 shares or 1.19% of the stock. Motco has 0.6% invested in Merck & Co., Inc. (NYSE:MRK) for 71,134 shares. Foster & Motley has invested 0.11% in Merck & Co., Inc. (NYSE:MRK). Trillium Asset Mgmt Limited Liability Company owns 468,262 shares for 2.07% of their portfolio. 149,984 are held by Sensato Invsts Lc. Pettee Investors reported 37,515 shares. Quantitative Systematic Strategies Lc stated it has 17,587 shares. Alley Limited Liability Company reported 83,606 shares stake. Bar Harbor Ser invested in 0.36% or 6,506 shares. Synovus Fin reported 387,962 shares stake. Parallax Volatility Advisers Limited Partnership accumulated 0.11% or 1.10 million shares.

Analysts await Merck & Co., Inc. (NYSE:MRK) to report earnings on May, 7. They expect $1.08 EPS, up 2.86% or $0.03 from last year’s $1.05 per share. MRK’s profit will be $2.79 billion for 19.20 P/E if the $1.08 EPS becomes a reality. After $1.04 actual EPS reported by Merck & Co., Inc. for the previous quarter, Wall Street now forecasts 3.85% EPS growth.

More notable recent Merck & Co., Inc. (NYSE:MRK) news were published by: Seekingalpha.com which released: “Merck extends partnership with NGM Biopharmaceuticals – Seeking Alpha” on March 20, 2019, also Seekingalpha.com with their article: “Reuters: UPS eyes health logistics market with home vaccine test – Seeking Alpha” published on March 22, 2019, Benzinga.com published: “FedEx Corporation (NYSE:FDX), Merck & Company, Inc. (NYSE:MRK) – FedEx’s Struggles May Be Less About Global Demand And More About ‘NotPetya’ – Benzinga” on March 21, 2019. More interesting news about Merck & Co., Inc. (NYSE:MRK) were released by: Seekingalpha.com and their article: “Merck’s Stock Signals Bearish Warning Signs – Seeking Alpha” published on March 11, 2019 as well as Seekingalpha.com‘s news article titled: “Wall Street Breakfast: EU Grants A Brexit Extension, But Not For Long – Seeking Alpha” with publication date: March 22, 2019.

Segment Wealth Management Llc increased Vanguard Group (VIG) stake by 49,750 shares to 66,365 valued at $6.50 million in 2018Q4. It also upped Broadcom Inc stake by 1,389 shares and now owns 18,415 shares. Spdr S&P Midcap 400 Etf Tr (MDY) was raised too.

Methode Electronics, Inc. (NYSE:MEI) Institutional Positions Chart



Source link

Leave a Reply